These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23102728)

  • 1. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
    Huang MH; Lee JH; Chang YJ; Tsai HH; Lin YL; Lin AM; Yang JC
    Mol Oncol; 2013 Feb; 7(1):112-20. PubMed ID: 23102728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
    PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
    Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
    Xie M; He J; He C; Wei S
    J Cell Biochem; 2015 Jun; 116(6):1019-27. PubMed ID: 25561332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
    Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
    Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
    Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
    Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
    Ninomiya K; Ohashi K; Makimoto G; Tomida S; Higo H; Kayatani H; Ninomiya T; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Sci Rep; 2018 Jan; 8(1):1955. PubMed ID: 29386539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Faber AC; Li D; Song Y; Liang MC; Yeap BY; Bronson RT; Lifshits E; Chen Z; Maira SM; García-Echeverría C; Wong KK; Engelman JA
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19503-8. PubMed ID: 19850869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.